MEDICORE INC
10-Q/A, 2000-11-16
ELECTRONIC COMPONENTS, NEC
Previous: APPLIED POWER INC, PRE 14A, 2000-11-16
Next: BANDAG INC, S-8, 2000-11-16




                               FORM 10-Q/A#1

                   SECURITIES AND EXCHANGE COMMISSION

                         Washington, D.C.  20549

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2000
                               ------------------

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For the transition period from           to
                               ---------    ---------

Commission file number 0-6906
                       ------

                             MEDICORE, INC.
         --------------------------------------------------------
          (Exact name of registrant as specified in its charter)

               Florida                                   59-0941551
---------------------------------------------       --------------------
(State or other jurisdiction of incorporation        (I.R.S. Employer
or organization)                                     Identification No.)

2337 West 76th Street, Hialeah, Florida                    33016
---------------------------------------                  ----------
(Address of principal executive offices)                 (Zip Code)

                           (305) 558-4000
          ----------------------------------------------------
          (Registrant's telephone number, including area code)

                           NOT APPLICABLE
    ---------------------------------------------------------------
    (Former name, former address and former fiscal year, if changed
                         since last report)

     Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15 (d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

Yes [x] or No [ ]

Common Stock Outstanding

     Common Stock, $.01 par value - 5,710,540 shares as of October 31, 2000

<PAGE>

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amended Quarterly Report on Form 10-Q/A#1 to
be signed on its behalf by the undersigned thereunto duly authorized.

                             MEDICORE, INC.

                                /s/ Daniel R. Ouzts

                             By---------------------------------
                                DANIEL R. OUZTS, Vice President/
                                Finance, Controller and Chief
                                Financial Officer

Dated:  November 16, 2000



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission